Kenya Chronic Obstructive Pulmonary Disease (COPD) Drug Market
The Kenya Chronic Obstructive Pulmonary Disease (COPD) Drug Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global Kenya Chronic Obstructive Pulmonary Disease (COPD) Drug market. This report explores all the key factors affecting the growth of the global Kenya Chronic Obstructive Pulmonary Disease (COPD) Drug market, including demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.
Get PDF Sample Report Now! @ www.prudentmarkets.com/sample-request/141658/
Report Overview
The Chronic Obstructive Pulmonary Disease (COPD) drug market size in Kenya stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period
Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by airflow limitation that is progressive and associated to an abnormal response of the lungs to noxious particles or gases. Smoking is the main risk factor of COPD. Exposure to occupational or domestic fumes, or previous infection can also cause the disease. In Kenya, COPD is estimated to cause the same amount of DALYs as ischemic heart disease, stroke and epilepsy indicating that it is grossly underdiagnosed and treated. There is a high prevalence of COPD among women due to the exposure to fumes from wood and charcoal used in cooking.
Market Drivers
The market is majorly driven by the rising prevalence of COPD in Kenya. Chronic Obstructive Pulmonary Disease (COPD) causes substantial burden of disease in low- and middle-income countries, but there are limited data from Africa.A Meta analysis of five spirometry-based studies from Africa reported a mean prevalence of COPD as 13.4%, ranging from 9.4 to 22.1%.
Smoking is the main risk factor for development of Chronic Obstructive Pulmonary Disease. According to WHO, about 86.1% of Kenyan adults are exposed to tobacco smoke in bars and night clubs and 24.8% of youth being exposed at home.
In Kenya, 7.2% of school-going adolescents smoke cigarettes, while 8.5% use other forms of tobacco products. Dyspnoea is the main reason for COPD having the 10th highest morbidity in low- and middle- income countries. Mortality increases with decreasing lung function, infective exacerbations and acute respiratory failure.
High levels of tuberculosis infection in Kenya also increases COPD prevalence.
To Know More About COVID-19 Impact On Kenya Chronic Obstructive Pulmonary Disease (COPD) Drug Market @ www.prudentmarkets.com/sample-request/141658/
Market Segmentation
By Drug Class:
On the basis of drug class, the chronic obstructive pulmonary disease (COPD) drug market is segmented into phosphodiestrase-4 inhibitors, long-acting bronchodilators, short-acting bronchodilators, methylxanthines and corticosteroids.
The rapid and short acting beta 2 agonists include salbutamol, fenoterol, terbutaline, pirbuterol and procaterol. Salmetrol and Formoterol are long-acting beta 2 agonists with prolonged bronchodilator action that lasts up to 12 hours.
By Route of Administration:
On the basis of route of administration, the asthma drug market can be segmented into oral drugs, inhalation drugs and parenteral route.
The inhaler segment includes dry powder, metered dose, and soft mist inhalers. The metered-dose inhalers (MDIs) segment dominates the market. This is majorly attributed to reliability, versatility, self-containment, easy availability, portability, and cost-efficient medical aerosol delivery option among others.
By Distribution Channel:
On the basis of distribution channel, the market for cardiovascular drugs can be segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. The hospital segment is expected to dominate the market throughout the forecast period
Major Players
Top drug makers are making sizeable investments in clinical trials focused on reducing Chronic Obstructive Pulmonary Disease exacerbations, in a move to develop advanced and more efficacious drugs for managing COPD. Players holding prominent position in the COPD drug market include Abbott Laboratories, F. Hoffmann-La Roche, Merck & Co., AstraZeneca, Cipla, GlaxoSmithKline, and Novartis AG.
Cipla is leading the respiratory therapeutics market in Kenya with its robust pipeline drugs like Duolin, Asthalin, Aerocort and Budecort.
Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.
Speak To Our Analyst For A Discussion On The Above Findings, And Ask For A Discount On The Report @ www.prudentmarkets.com/discount-request/141658/
The report covers the competitive analysis of the market. As the demand is driven by a buyer's paying capacity and the rate of item development, the report shows the important regions that will direct growth. This section exclusively shares insight into the budget reports of big-league members of the market helping key players and new entrants understand the potential of investments in the Global Kenya Chronic Obstructive Pulmonary Disease (COPD) Drug Market. It can be better employed by both traditional and new players in the industry for complete know-how of the market.
Strategic Points Covered in Table of Content of Global Kenya Chronic Obstructive Pulmonary Disease (COPD) Drug Market:
Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Kenya Chronic Obstructive Pulmonary Disease (COPD) Drug market
Chapter 2: Exclusive Summary - the basic information of the Kenya Chronic Obstructive Pulmonary Disease (COPD) Drug Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Kenya Chronic Obstructive Pulmonary Disease (COPD) Drug
Chapter 4: Presenting the Kenya Chronic Obstructive Pulmonary Disease (COPD) Drug Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the Kenya Chronic Obstructive Pulmonary Disease (COPD) Drug market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source
Any Questions? Feel Free To Enquire Here. We Will put you on the Right Path @ www.prudentmarkets.com/enquiry-request/141658/
Free Customization on the basis of client requirements on Immediate purchase:
1- Free country-level breakdown of any 5 countries of your interest.
2- Competitive breakdown of segment revenue by market players.
Customization of the Report:
This report can be customized to meet the client's requirements. Please connect with our sales team ([email protected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +91 83560 50278 || USA/Canada(Toll Free): 1800-601-6071 to share your research requirements.
Get ready to Recognize the pros and cons of the regulatory framework, local reforms, and its effect on the Industry. Understand how the Leaders in Intelligent Network are keeping themselves one stage forward with our most up-to-date survey analysis.
In conclusion, the Kenya Chronic Obstructive Pulmonary Disease (COPD) Drug Market report is a genuine source for accessing the research data which is projected to exponentially grow your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis and PESTLE analysis is also incorporated in the report.
Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: [email protected]
Web: www.prudentmarkets.com
About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.
This release was published on openPR.
